Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis

Autor: George J Wan, Ishveen Chopra, John Niewoehner, Samuel F Hunter

Publikováno v: Drugs in Context, Vol 9, Pp 1-7 (2020)

Background: Relapses are common in patients with multiple sclerosis (MS) even after the use of disease-modifying therapies. Repository corticotropin injection (RCI), plasmapheresis (PMP), and intravenous immunoglobulin (IVIg) may be utilized as alter

Externí odkaz: https://doaj.org/article/23e6ed5f05954d1eaef8f376ecc49e2e

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

Autor: Sibyl Wray, Florian Then Bergh, Annette Wundes, Douglas L. Arnold, Jelena Drulovic, Elzbieta Jasinska, James D. Bowen, Donald Negroski, Robert T. Naismith, Samuel F. Hunter, Mark Gudesblatt, Hailu Chen, Jennifer Lyons, Sai L. Shankar, Shivani Kapadia, Jason P. Mendoza, Barry A. Singer

Publikováno v: Advances in Therapy. 39:1810-1831

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::77ad905de880352f36f4e160a876434e
https://doi.org/10.1007/s12325-022-02068-7

Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies

Autor: Basil Sharrack, Ho Jin Kim, Rany A Aburashed, Thomas F. Scott, Andrew T. Chan, Carlo Pozzilli, Daniel Kantor, Richard A L Macdonell, Nadia Daizadeh, Dominique Dive, Samuel F. Hunter, Jan Lycke, Raed Alroughani, Darren P Baker, Heinz Wiendl, Sara Eichau, Luke Chung, Patrick Vermersch

Publikováno v: Neurology and Therapy
Hunter, Samuel F; Aburashed, Rany A; Alroughani, Raed; Chan, Andrew; Dive, Dominique; Eichau, Sara; Kantor, Daniel; Kim, Ho Jin; Lycke, Jan; Macdonell, Richard A L; Pozzilli, Carlo; Scott, Thomas; Sharrack, Basil; Wiendl, Heinz; Chung, Luke; Daizadeh, Nadia; Baker, Darren P; Vermersch, Patrick (2021). Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies. Neurology and therapy, 10(2), pp. 803-818. Springer 10.1007/s40120-021-00262-3

Introduction In the 2-year CARE-MS trials (NCT00530348; NCT00548405) in patients with relapsing–remitting multiple sclerosis, alemtuzumab showed superior efficacy versus subcutaneous interferon beta-1a. Efficacy was maintained in two consecutive ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13d7429be1a1b274c059ed9b671eb848
https://doi.org/10.1007/s40120-021-00262-3

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

Autor: Luke Chung, Samuel F. Hunter, Barry A Singer, Antonio Bertolotto, Guillermo Izquierdo, Lobat Hashemi, Tjalf Ziemssen, Nadia Daizadeh, William David Honeycutt, Elisabeth Gulowsen Celius, Dimos-Dimitrios Mitsikostas, Salman Afsar, Barbara Kornek, Tamara Miller, Peter A. Senior, Rafael Arroyo, Giancarlo Comi, Eva Havrdova

Publikováno v: Neurology and Therapy, Vol 9, Iss 2, Pp 443-457 (2020)
Neurology and Therapy

Introduction In clinical trials of alemtuzumab, autoimmune thyroid adverse events (AEs) were frequent. Here, we assess the impact of thyroid AEs on health-related quality of life (HRQL) in alemtuzumab-treated patients with relapsing-remitting multipl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11cd63ac06d46041c4b97e966e3dc953
https://doaj.org/article/3bcc37fc46e84de69be4eb2c49df7148

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

Autor: Sibyl, Wray, Florian, Then Bergh, Annette, Wundes, Douglas L, Arnold, Jelena, Drulovic, Elzbieta, Jasinska, James D, Bowen, Donald, Negroski, Robert T, Naismith, Samuel F, Hunter, Mark, Gudesblatt, Hailu, Chen, Jennifer, Lyons, Sai L, Shankar, Shivani, Kapadia, Jason P, Mendoza, Barry A, Singer

Publikováno v: Advances in therapy. 39(4)

Diroximel fumarate (DRF) is an oral fumarate for relapsing multiple sclerosis (MS) with the same active metabolite as dimethyl fumarate (DMF). DRF has a safety/efficacy profile similar to DMF but with improved gastrointestinal (GI) tolerability and l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bd41959579e39a5ea86823fcb638619b
https://pubmed.ncbi.nlm.nih.gov/35211872